An interventional study of GPX® Embolic Device in Embolization, Hypervascular Tumor and Renal Angiomyolipoma, sponsored by Fluidx Medical Technology, Inc.. Completed at 20 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Fluidx Medical Technology, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,144 studies in Carcinoma, Renal Cell with a site in United States — 155 open to participants now, 278 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.
Among the 1,144 studies in Carcinoma, Renal Cell with a site in United States, this one is the 242nd largest by enrollment of the 1,010 interventional ones that give a count, is one of 38 that started in 2024, is one of 98 with no phase, and was the 1,050th registered.
2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.
Browse Carcinoma, Renal Cell studies →155 of the 1,144 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
University of Oklahoma · Sites in United States
Ages 18–100 · Men only
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 489 · Phase 2 531 · Phase 3 74 · Phase 4 10
First in 1990; this study’s year is marked. 38 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 114 is above the median of 43 across 1,569 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 40 across the 1,010 interventional studies, 100 across the 87 observational. Of the 795 that completed or were terminated, 338 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
468 of 1,144 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Fluidx Medical Technology, Inc. as lead sponsor.
Fluidx Medical Technology, Inc. has 1 study filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
97 of the studies in Carcinoma, Renal Cell with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05678673Phase 3ExelixisStudy of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | 2026-12-15 |
| NCT03592472Phase 3Xynomic Pharmaceuticals, Inc.A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | 2026-12-30 |
| NCT03873402Phase 3Bristol-Myers SquibbA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | 2027-03-11 |
| NCT05863351Phase 3ECOG-ACRIN Cancer Research GroupFocused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study | 2027-08-31 |
Add all 97 to your calendar (.ics) → With an account.
Among the 1,144 studies in Carcinoma, Renal Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in the USA, New Zealand, and Canada.
The investigation is a single-arm, open-label, non-randomized, prospective, multicenter, multinational pivotal study. Subjects will undergo distal embolization in the peripheral vasculature, including vascular tumors, renal embolizations, and portal vein branches, with the GPX® Embolic Device and will then be followed 30-days post-procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presents with need for peripheral embolization where there is a desire for distal vessel bed penetration including:
Exclusion Criteria:
Intra-procedural exclusion criteria:
13. Presence of persistent, flow-limiting vasospasm that is not responsive to chemical or mechanical interventions 14. Presence of collateral pathways potentially endangering normal territories during embolization 15. Blood flow precludes safe delivery of embolic material (e.g., arteriovenous shunting or high, unpredictable flow exists) 16. Anatomy that precludes advancement of the delivery device to target vessel embolization site or delivery of embolic material 17. Dissection in the target vessel 18. The delivery device has already been used with an ionic contrast agent (e.g., Conray® (iothalamate meglumine injection USP 60%), Guerbet)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: GPX® Embolic Device
Treatment includes distal embolization in the peripheral vasculature of vascular tumors, renal embolization, and portal vein branches
Number of Participants With Freedom From Major Adverse Events (MAEs)
MAEs are defined as: * Nontarget embolization with ischemia in an unintended anatomical area * Systemic allergic and/or toxic reaction to the GPX Embolic Device * Catheter entrapment and/or breakage * Culture-proven abscess in target organ/tissue * Embolization-related death
Time frame: Index procedure through 30-day follow-up
Number of Participants With Successful Delivery of the GPX Embolic Device to the Target Vessel Embolization Site(s)
Determined by the investigator during procedure
Time frame: During procedure (an average of 1 to 3 hours) after device (GPX) delivery
Number of Participants With Successful Occlusion of Flow Immediately Beyond the Target Vessel Embolization Site(s)
Determined by the core lab via comparison of the pre- and final post-embolization images
Time frame: End of procedure, an average of 1 to 3 hours
Number of Participants With Occurrence of Device-related Adverse Events (AE) Through 30 Days Post-index Procedure
Time frame: 30-day follow-up
Number of Participants With Occurrence of Adjunctive Embolization Agent Usage During the Embolization Procedure
Time frame: End of procedure, an average of 1 to 3 hours
Number of Participants With Occurrence of Catheter Occlusion Due to the GPX Embolic Material
Time frame: End of procedure, an average of 1 to 3 hours
| Milestone | GPX® Embolic Device |
|---|---|
| Started | 114 |
| Completed | 113 |
| Not completed | 1 |
MAEs are defined as: * Nontarget embolization with ischemia in an unintended anatomical area * Systemic allergic and/or toxic reaction to the GPX Embolic Device * Catheter entrapment and/or breakage * Culture-proven abscess in target organ/tissue * Embolization-related death
| Participants | GPX® Embolic Device |
|---|---|
| Number of Participants With Freedom From Major Adverse Events (MAEs) | 113 |
Determined by the investigator during procedure
| Participants | GPX® Embolic Device |
|---|---|
| Number of Participants With Successful Delivery of the GPX Embolic Device to the Target Vessel Embolization Site(s) | 114 |
Determined by the core lab via comparison of the pre- and final post-embolization images
| Participants | GPX® Embolic Device |
|---|---|
| Number of Participants With Successful Occlusion of Flow Immediately Beyond the Target Vessel Embolization Site(s) | 109 |
| Participants | GPX® Embolic Device |
|---|---|
| Number of Participants With Occurrence of Device-related Adverse Events (AE) Through 30 Days Post-index Procedure | 6 |
| Participants | GPX® Embolic Device |
|---|---|
| Number of Participants With Occurrence of Adjunctive Embolization Agent Usage During the Embolization Procedure | 1 |
| Participants | GPX® Embolic Device |
|---|---|
| Number of Participants With Occurrence of Catheter Occlusion Due to the GPX Embolic Material | 0 |
Collected over All adverse events (AEs) were collected from the start of the embolization procedure for all enrolled subjects and assessed throughout the study (30-day follow-up).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GPX® Embolic Device | 0/114 (0%) | 30/114 (26.3%) | 19/114 (16.7%) |
| Event | GPX® Embolic Device |
|---|---|
| Post embolisation syndromeInjury, poisoning and procedural complications | 12/114 |
| HyponatraemiaMetabolism and nutrition disorders | 2/114 |
| Skin necrosisSkin and subcutaneous tissue disorders | 2/114 |
| CholangitisHepatobiliary disorders | 2/114 |
| Abdominal pain upperGastrointestinal disorders | 1/114 |
| AbscessInfections and infestations | 1/114 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/114 |
| AnaemiaBlood and lymphatic system disorders | 1/114 |
| CholecystitisHepatobiliary disorders | 1/114 |
| Flank painMusculoskeletal and connective tissue disorders | 1/114 |
| Event | GPX® Embolic Device |
|---|---|
| Post embolisation syndromeInjury, poisoning and procedural complications | 19/114 |
| Age, Continuous(years) | GPX® Embolic Device |
|---|---|
| Mean | 61.1 ± 14.1 |
| Sex: Female, Male(Participants) | GPX® Embolic Device |
|---|---|
| Female | 56 |
| Male | 58 |
| Ethnicity (NIH/OMB)(Participants) | GPX® Embolic Device |
|---|---|
| Hispanic or Latino | 15 |
| Not Hispanic or Latino | 98 |
| Unknown or Not Reported | 1 |
| Race/Ethnicity, Customized(Participants) | GPX® Embolic Device |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 6 |
| Black or African American | 11 |
| Native Hawaiian or other Pacific Islander | 1 |
| White | 81 |
| Other | 14 |
| Subject chose not to disclose | 1 |
| Region of Enrollment(participants) | GPX® Embolic Device |
|---|---|
| New Zealand | 12 |
| Canada | 15 |
| United States | 87 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2024 to primary completion in Jan 2026, 14 months.
Results were first posted in Nov 2026, 9 months after primary completion.
Of 127 interventional studies with no phase under Carcinoma, Renal Cell, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 114. This study's 14 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion May 2026 → Jan 2026 and completion Sep 2026 → Jan 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.